Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition
CDK8/19 kinases, which mediate transcriptional reprogramming, have become an active target for cancer drug discovery. Several small-molecule CDK8/19 inhibitors showed in vivo efficacy and two have entered clinical trials, with no significant toxicities reported. However, Clarke et al. (eLife 2016; 5...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-11-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/8/11/1413 |
| _version_ | 1797720524577570816 |
|---|---|
| author | Mengqian Chen Jing Li Jiaxin Liang Zanshé S. Thompson Katie Kathrein Eugenia V. Broude Igor B. Roninson |
| author_facet | Mengqian Chen Jing Li Jiaxin Liang Zanshé S. Thompson Katie Kathrein Eugenia V. Broude Igor B. Roninson |
| author_sort | Mengqian Chen |
| collection | DOAJ |
| description | CDK8/19 kinases, which mediate transcriptional reprogramming, have become an active target for cancer drug discovery. Several small-molecule CDK8/19 inhibitors showed in vivo efficacy and two have entered clinical trials, with no significant toxicities reported. However, Clarke et al. (eLife 2016; 5; e20722) found severe systemic toxicity associated with two potent CDK8/19 inhibitors, Cmpd3 (CCT251921) and Cmpd4 (MSC2530818), and suggested that their toxicity was due to on-target effects. Here, we compared five CDK8/19 inhibitors: Cmpd3, Cmpd4, Senexin B, 16-didehydro-cortistatin A (dCA) and 15w, in different assays. Only Cmpd4 showed striking toxicity in developing zebrafish. In cell-based assays for CDK8 and CDK19 inhibition, Cmpd3, Cmpd4, dCA and 15w showed similar low-nanomolar potency and efficacy against CDK8 and CDK19, while Senexin B was less potent. Only dCA produced sustained inhibition of CDK8/19-dependent gene expression. While toxicity of different compounds did not correlate with their effects on CDK8 and CDK19, kinome profiling identified several off-target kinases for both Cmpd3 and Cmpd4, which could be responsible for their toxicity. Off-target activities could have been achieved in the study of Clarke et al. due to high in vivo doses of Cmpd3 and Cmpd4, chosen for the ability to inhibit STAT1 S727 phosphorylation in tumor xenografts. We show here that STAT1 S727 phosphorylation is induced by various cytokines and stress stimuli in CDK8/19-independent manner, indicating that it is not a reliable pharmacodynamic marker of CDK8/19 activity. These results illustrate the need for careful off-target analysis and dose selection in the development of CDK8/19 inhibitors. |
| first_indexed | 2024-03-12T09:20:47Z |
| format | Article |
| id | doaj.art-f622691e8eef42439140685559054837 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-12T09:20:47Z |
| publishDate | 2019-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-f622691e8eef424391406855590548372023-09-02T14:32:34ZengMDPI AGCells2073-44092019-11-01811141310.3390/cells8111413cells8111413Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target InhibitionMengqian Chen0Jing Li1Jiaxin Liang2Zanshé S. Thompson3Katie Kathrein4Eugenia V. Broude5Igor B. Roninson6Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208, USADepartment of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208, USADepartment of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208, USADepartment of Biomedical Engineering, College of Engineering and Computing, University of South Carolina, Columbia, SC 29208, USADepartment of Biology, University of South Carolina, Columbia, SC 29208, USADepartment of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208, USADepartment of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208, USACDK8/19 kinases, which mediate transcriptional reprogramming, have become an active target for cancer drug discovery. Several small-molecule CDK8/19 inhibitors showed in vivo efficacy and two have entered clinical trials, with no significant toxicities reported. However, Clarke et al. (eLife 2016; 5; e20722) found severe systemic toxicity associated with two potent CDK8/19 inhibitors, Cmpd3 (CCT251921) and Cmpd4 (MSC2530818), and suggested that their toxicity was due to on-target effects. Here, we compared five CDK8/19 inhibitors: Cmpd3, Cmpd4, Senexin B, 16-didehydro-cortistatin A (dCA) and 15w, in different assays. Only Cmpd4 showed striking toxicity in developing zebrafish. In cell-based assays for CDK8 and CDK19 inhibition, Cmpd3, Cmpd4, dCA and 15w showed similar low-nanomolar potency and efficacy against CDK8 and CDK19, while Senexin B was less potent. Only dCA produced sustained inhibition of CDK8/19-dependent gene expression. While toxicity of different compounds did not correlate with their effects on CDK8 and CDK19, kinome profiling identified several off-target kinases for both Cmpd3 and Cmpd4, which could be responsible for their toxicity. Off-target activities could have been achieved in the study of Clarke et al. due to high in vivo doses of Cmpd3 and Cmpd4, chosen for the ability to inhibit STAT1 S727 phosphorylation in tumor xenografts. We show here that STAT1 S727 phosphorylation is induced by various cytokines and stress stimuli in CDK8/19-independent manner, indicating that it is not a reliable pharmacodynamic marker of CDK8/19 activity. These results illustrate the need for careful off-target analysis and dose selection in the development of CDK8/19 inhibitors.https://www.mdpi.com/2073-4409/8/11/1413cdk8cdk19kinome profilingzebrafish toxicity assaysstat1 serine phosphorylation |
| spellingShingle | Mengqian Chen Jing Li Jiaxin Liang Zanshé S. Thompson Katie Kathrein Eugenia V. Broude Igor B. Roninson Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition Cells cdk8 cdk19 kinome profiling zebrafish toxicity assays stat1 serine phosphorylation |
| title | Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition |
| title_full | Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition |
| title_fullStr | Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition |
| title_full_unstemmed | Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition |
| title_short | Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition |
| title_sort | systemic toxicity reported for cdk8 19 inhibitors cct251921 and msc2530818 is not due to target inhibition |
| topic | cdk8 cdk19 kinome profiling zebrafish toxicity assays stat1 serine phosphorylation |
| url | https://www.mdpi.com/2073-4409/8/11/1413 |
| work_keys_str_mv | AT mengqianchen systemictoxicityreportedforcdk819inhibitorscct251921andmsc2530818isnotduetotargetinhibition AT jingli systemictoxicityreportedforcdk819inhibitorscct251921andmsc2530818isnotduetotargetinhibition AT jiaxinliang systemictoxicityreportedforcdk819inhibitorscct251921andmsc2530818isnotduetotargetinhibition AT zanshesthompson systemictoxicityreportedforcdk819inhibitorscct251921andmsc2530818isnotduetotargetinhibition AT katiekathrein systemictoxicityreportedforcdk819inhibitorscct251921andmsc2530818isnotduetotargetinhibition AT eugeniavbroude systemictoxicityreportedforcdk819inhibitorscct251921andmsc2530818isnotduetotargetinhibition AT igorbroninson systemictoxicityreportedforcdk819inhibitorscct251921andmsc2530818isnotduetotargetinhibition |